Comparative Pharmacology
Head-to-head clinical analysis: DRICORT versus KENALOG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRICORT versus KENALOG.
DRICORT vs KENALOG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with predominant glucocorticoid activity; binds to glucocorticoid receptors, modulating gene expression and suppressing inflammatory mediators (e.g., prostaglandins, leukotrienes) and immune cell function.
Triamcinolone acetonide is a synthetic corticosteroid with potent glucocorticoid and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced synthesis of prostaglandins and leukotrienes. It also suppresses cytokine production and immune cell migration.
DRICORT (dexamethasone) typical adult dose: 0.5-9 mg/day orally in divided doses every 6-12 hours, or 0.5-24 mg IV/IM once or divided. Anti-inflammatory: 0.75-9 mg/day PO/IV in 2-4 divided doses. Severe conditions: up to 16 mg/day in divided doses. Short-term high-dose: up to 40-100 mg IV push for specific indications.
Kenalog (triamcinolone acetonide) 40-80 mg intramuscularly (deep gluteal) every 4 weeks; or 0.5-1 mg/kg intravenously every 24 hours (for acute conditions).
None Documented
None Documented
Terminal elimination half-life is 10-12 hours in adults with normal renal function, allowing twice-daily dosing.
Terminal half-life ~2-5 hours (triamcinolone acetonide); clinical duration prolonged due to crystalline depot formulation
Primarily renal (80-85% as unchanged drug and metabolites), with 15-20% excreted in feces via biliary elimination.
Renal (primarily as metabolites), ~30% unchanged; biliary/fecal minor (≤10%)
Category C
Category C
Corticosteroid
Corticosteroid